Investing.com - Financial Markets Worldwide

PharmAbcine Inc (208340)

KOSDAQ
Currency in KRW
2,915
0(0.00%)
Closed·
208340 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
Trading near 52-week Low
208340 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
2,8953,435
52 wk Range
2,8953,435
Key Statistics
Edit
Bid/Ask
2,915.00 / 2,940.00
Prev. Close
2,915
Open
3,260
Day's Range
2,895-3,435
52 wk Range
2,895-3,435
Volume
-
Average Volume (3m)
2.55M
1-Year Change
0%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
208340 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 11
Stock generally trades with low price volatility
Unlock InvestingPro

PharmAbcine Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

PharmAbcine Inc Company Profile

PharmAbcine Inc., a clinical-stage biotech company, develops human therapeutic monoclonal antibody (mAb) for the treatment of neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for various spectrum of indications from oncology, immuno-oncology, ophthalmology, and pulmonology. The company also develops TTAC0001, an anti-angiogenic that neutralizes the VEGF/VEGFR2 pathway; PMC-309, a monoclonal antibody that targets the negative immune checkpoint human VISTA; PMC-402, a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization for solid tumors; and PMC-403, a monoclonal antibody that targets the human TIE2, which regulate the angiogenesis and vessel maturation in endothelial cells. In addition, its pipeline products for the development new candidates such as PMC-005BL, PMC-122, PMC-401, and PMC-401s. The company has a strategic partnership with Samsung Biologics Co.,Ltd. for the development and manufacturing of oncology and neovascular treatment; a clinical trial collaboration with MSD for the Phase II study in mTNBC; and a research collaboration agreement with LegoChem Biosciences Inc. (LCB) to provide PMC-403, a preclinical pipeline to LCB for combination research using PMC-403 and LCB's ADC for solid tumors. PharmAbcine Inc. is was founded in 2008 and based in Daejeon, South Korea.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
39
Market
South Korea

Compare 208340 to Peers and Sector

Metrics to compare
208340
Peers
Sector
Relationship
P/E Ratio
−55.0x−8.4x−0.5x
PEG Ratio
−0.66−0.070.00
Price/Book
4.9x2.2x2.6x
Price / LTM Sales
40.7x17.0x3.3x
Upside (Analyst Target)
-0.0%43.3%
Fair Value Upside
Unlock4.8%6.9%Unlock

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-7.57 / --
Revenue / Forecast
1.90B / --
EPS Revisions
a
a
Unlock
Last 90 days

208340 Income Statement

FAQ

What Stock Exchange Does PharmAbcine Trade On?

PharmAbcine is listed and trades on the KOSDAQ stock exchange.

What Is the Stock Symbol for PharmAbcine?

The stock symbol for PharmAbcine is "208340."

What Is the PharmAbcine Market Cap?

As of today, PharmAbcine market cap is 233.76B.

What Is PharmAbcine's Earnings Per Share (TTM)?

The PharmAbcine EPS (TTM) is -71.20.

From a Technical Analysis Perspective, Is 208340 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has PharmAbcine Stock Split?

PharmAbcine has split 2 times.

How Many Employees Does PharmAbcine Have?

PharmAbcine has 39 employees.

What is the current trading status of PharmAbcine (208340)?

As of 11 Aug 2025, PharmAbcine (208340) is trading at a price of 2,915.00, with a previous close of 2,915.00. The stock has fluctuated within a day range of 2,895.00 to 3,435.00, while its 52-week range spans from 2,895.00 to 3,435.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.